As of 2025-12-23, the EV/EBITDA ratio of Y-mAbs Therapeutics, Inc (YMAB) is -15.86. EV/EBITDA ratio is calculated by dividing the enterprise value by the TTM EBITDA. YMAB's latest enterprise value is 328.95 mil USD. YMAB's TTM EBITDA according to its financial statements is -20.75 mil USD. Dividing these 2 quantities gives us the above YMAB EV/EBITDA ratio.
Note: valuation result may not be accurate due to the company's negative EBITDA.
| Range | Selected | |
| Trailing P/E multiples | 15.4x - 17.2x | 15.6x |
| Forward P/E multiples | 35.3x - 57.2x | 55.2x |
| Fair Price | (14.76) - (6.49) | (14.79) |
| Upside | -271.5% - -175.4% | -271.8% |
| Date | EV/EBITDA |